Domestic Innovative Medicines from TUBITAK MARTEK Company CT Pharma Research
TÜBİTAK MARTEK company developed products previously brought from abroad for research purposes in cancer patients in its own laboratories, within the scope of a joint project with CT Pharma Research, Medicana Hospitals and TÜBİTAK MARTEK. Thanks to the products whose technical analyzes were made and which became usable in research units, foreign exchange outflows were stopped and drugs were made cheaper, preventing foreign exchange loss.
With the production of Ascorbic Acid 50g/100ml, Ascorbic Acid 15g/100ml and Curcumin 15mg/ml products in our country, the decrease in the import of know-how from abroad; paving the way for the export of the products to be developed to developing markets, considering the production possibilities in Turkey; ensuring the export of technical files abroad with the know-how to be developed; It is aimed to facilitate access to innovative medicines.
CT Pharma Research General Manager Dr. Şerhan Şimşek explained the activities of CT Pharma Research in the R&D laboratories of TÜBİTAK MARTEK for the development of conventional and biotechnological drugs with these words: “Formulation development; analytical method development; analytical method validations; scale up formulation studies; stability studies; determination of critical process parameters; We carry out CTD module 3 preparation activities in line with the regulations of the Ministry of Health, General Directorate of Pharmaceuticals and Pharmacy, required for drug licensing”.
Dr. Şerhan Şimşek said, “CT Pharma Research also applies WHO, USP, EP, ICH international standards and EMEA guidelines. We follow the latest technological developments with state of art equipment and provide product development services by making use of the latest technology. Our conventional drug development capacity at CT Pharma Research includes tablets, film tablets, liquid suspensions, dry powder suspensions, capsules, parenteral (IM, IV), semi-solid (pomade, cream), all kinds of liquid drops, sprays, solutions; Our biotech drug development capacity is available as therapeutic peptide development (lyophilized and parenteral ampoule). We have already completed the development of more than 100 finished product registration dossiers for 14 domestic pharmaceutical companies.” said.
Explaining that their projects are supported by TEYDEB, “Development of Rasagiline 1 mg Tablets” and “Development of Parenteral Biotechnological Product Equivalent in Lyophilized Powder Dosage Form Containing Bivaluridine from Direct Thrombin Inhibitors” Dr. Şerhan Şimşek stated that they applied for TEYDEP support for the parenteral product containing Octreotide.
Stating that CT Pharma Research decided to expand abroad in 2017, Dr Şimşek said that they started bilateral talks to operate in Belgium, England and Saudi Arabia.
Dr Şimşek noted that the work on the opening of an office in the Saudi Arabian KAUST (King Abdullah University Science and Technology) region has reached the final stage.
